2023 European Society for Medical Oncology (ESMO) Annual Congress
ESMO 2023 Prostate Cancer
- ESMO 2023: Delineating Staging Pelvic Lymph Node Dissection Before Radiotherapy and Positioning Primary Prostatectomy
- ESMO 2023: How Much Systemic Treatment Is Needed and How Long?
- ESMO 2023: Dose Intensification and Field Expansion of External Beam Radiation Therapy
- ESMO 2023: Tolerance and Long-Term Side-Effects
- ESMO 2023: Usefulness and Limitations of PSMA Imaging/PET in High-Risk Localized Disease
ESMO 2023 Bladder Cancer
- ESMO 2023: Global Access Considerations in Systemic Treatment of Genitourinary Cancers
- ESMO 2023: Current Peri-Operative Trial Designs and Endpoints: What Do They Mean?
- ESMO 2023: State-of-the-Art in Adjuvant Treatment of Urothelial Cancer
- ESMO 2023: Antibody Drug Conjugates and FGFR-Directed Therapies: New Toxicities
- ESMO 2023: Screening New Agents in “Window of Opportunity” Neoadjuvant Trials
ESMO 2023 Kidney Cancer
- ESMO 2023: State-of-the-Art in Adjuvant Treatment of Renal Cell Carcinoma
- ESMO 2023: Comparative Effectiveness of Second Line Treatment with Cabozantinib in Patients with Metastatic Clear Cell RCC after First Line Treatment with Ipilimumab + Nivolumab vs. PD-1/L1 inhibitor + TKI
- ESMO 2023: Advances in the Molecular Understanding of GU Cancers: The Next Generation of Therapeutic Targets
- ESMO 2023: Prediction of Toxicity in Current Systemic Treatment of Genitourinary Cancers
- ESMO 2023: CLEAR Trial, Post Hoc Analysis of the Tumor Response by Baseline Metastases in Patients with Renal Cell Carcinoma Treated with Lenvatinib + Pembrolizumab vs Sunitinib
ESMO 2023 Testicular and Penile Cancer
ESMO 2023 Press Releases
- Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments
- Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with BALVERSA® (erdafitinib) vs Chemotherapy
- Amgen to Present New Research from Oncology Portfolio and Pipeline at ESMO 2023
- Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
- Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma